This information is provided for shareholders who are U.S. taxpayers and it may not be relevant for other persons. It is for information purposes only and does not constitute tax advice. Any tax information in this communication is not intended or written to be used, and cannot be used, by any person or entity for the purpose of (i) avoiding penalties that may be imposed on any taxpayer or (ii) promoting, marketing or recommending to another party any matters addressed herein.
Centessa Pharmaceuticals plc (“Centessa”) believes that it would not be classified as a Passive Foreign Investment Company ("PFIC") for the tax year ending December 31, 2024. However, the determination of PFIC status is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Accordingly, Centessa cannot provide any assurance that it, or any of its subsidiaries, has not been, is not, or will not be treated as a PFIC for any past, current or future tax year.
The U.S. tax rules regarding PFICs are very complex and investors are strongly urged to consult their own tax advisor regarding the U.S. tax consequences of the PFIC rules to your investment in Centessa. Please consult your personal tax advisor with respect to the potential material adverse U.S. tax consequences if Centessa or any of its subsidiaries were to become a PFIC.